This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Vesugen (Lys-Glu-Asp) (20 mg Vial)
This information is for research and educational use only.
Quick Reference
What is Vesugen (Lys-Glu-Asp)?
Research overview based on the cited scientific literature.
Goal: Support vascular endothelial function and cellular renewal over time[2].
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality[10].
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Vesugen (Lys-Glu-Asp) studied?
Vesugen (KED) is a tripeptide derived from amino acids associated with vascular wall proteins[1]. Research indicates it may support vascular endothelial cell proliferation by modulating the expression of Ki-67, a protein closely associated with cell division[2]. The peptide is hypothesized to interact with promoter regions of the Ki-67 gene, potentially influencing epigenetic regulation[3]. Additional studies suggest Vesugen may normalize endothelin-1 expression and increase sirtuin-1 (SIRT-1) expression in vascular endothelial cells[4].
What does the research report about Vesugen (Lys-Glu-Asp)?
Observations from preclinical and cell culture research.
May support vascular endothelial cell proliferation and renewal through Ki-67 gene regulation[2][3].
Research suggests potential neuroprotective properties; oral application improved memory and attention in elderly individuals with functional CNS disorders[5].
May restore synaptic plasticity in in vitro models of Alzheimer’s disease[6].
Generally well tolerated in reported studies; occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on Vesugen (Lys-Glu-Asp)?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
